Antibody pharmaceuticals for thrombo-hemostatic disease

Successful thrombo-embolectomy in long-standing thrombo-embolic pulmonary hypertension.

Lifestyle and Hemostatic Risk Factors for Ischemic Heart Disease

We have recently shown that fibrin D-dimer, tissue plasminogen activator (tPA) antigen, von Willebrand factor antigen, fibrinogen, plasma viscosity, and white cell count are associated with subsequent ischemic heart disease (IHD) in men aged 49 to 65 years in the Caerphilly Study from South Wales. We now report the contribution of major lifestyle factors to plasma levels of these new risk predi...

Hemostatic defects in end stage liver disease.

End stage liver disease results in a complex and variably severe failure of hemostasis that predisposes to abnormal bleeding. The diverse spectrum of hemostatic defects includes impaired synthesis of clotting factors, excessive fibrinolysis, disseminated intravascular coagulation, thrombocytopenia, and platelet dysfunction. Hemostasis screening tests are used to assess disease severity and moni...

Liver Disease and Hemostatic (Dys)function.

Cirrhosis presents with decreased procoagulant factors as a consequence of the impaired synthetic capacity of the liver. This was taken as evidence to explain the abnormalities of the coagulation tests prothrombin time (PT) and activated partial thromboplastin time (aPTT) and the bleeding events that occur in these patients. It was for long time (and probably is still) common practice to test p...

Hemostatic function and coronary artery disease.

To the Editor: The lack of an independent relationship between fibrinogen level and recurrent coronary events reported by Moss et al1 in their recent article is at variance with previous evidence linking fibrinogen to coronary artery disease in individuals with and without preexisting cardiovascular disease.2 The fibrinogen levels reported by Moss et al are high in both patients who had recurre...